Related references
Note: Only part of the references are listed.Knocking Out Sigma-1 Receptors Reveals Diverse Health Problems
Simon Couly et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2022)
Intravenous arketamine for treatment-resistant depression: open-label pilot study
Gustavo C. Leal et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2021)
Risk of neuropsychiatric disorders in offspring of COVID-19-infected pregnant women and nutritional intervention
Kenji Hashimoto
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2021)
Recent progress of antiviral therapy for coronavirus disease 2019
Mengmeng Zhao et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders
Tangui Maurice
EXPERT OPINION ON DRUG DISCOVERY (2021)
Why do SARS-CoV-2 NSPs rush to the ER?
Maryline Santerre et al.
JOURNAL OF NEUROLOGY (2021)
COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays
Xueqing Wang et al.
MEDICINAL RESEARCH REVIEWS (2021)
Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: A review of the literature and recommendations for the COVID-19 pandemic
Anna Zimmer et al.
BRAIN BEHAVIOR AND IMMUNITY (2021)
Ketamine in COVID-19 patients: Thinking out of the box
Karolina Akinosoglou et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA
Maxime Taquet et al.
LANCET PSYCHIATRY (2021)
Connecting With Patients-The Missing Links
Lisa Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Current status of potential therapeutic candidates for the COVID-19 crisis
Jiancheng Zhang et al.
BRAIN BEHAVIOR AND IMMUNITY (2020)
Nervous system involvement after infection with COVID-19 and other coronaviruses
Yeshun Wu et al.
BRAIN BEHAVIOR AND IMMUNITY (2020)
Consider Adjunctive Ketamine in Mechanically Ventilated Coronavirus Disease-2019 Patients
Jamel Ortoleva
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA (2020)
Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019 A Review
Adeel S. Zubair et al.
JAMA NEUROLOGY (2020)
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
David E. Gordon et al.
NATURE (2020)
Drug researchers pursue new lines of attack against COVID-19
Charlotte Harrison
NATURE BIOTECHNOLOGY (2020)
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine
Kenji Hashimoto
BIOCHEMICAL PHARMACOLOGY (2020)
Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study
Jiancheng Zhang et al.
BRAIN BEHAVIOR AND IMMUNITY (2020)
Pathological Aspects of COVID-19 as a Conformational Disease and the Use of Pharmacological Chaperones as a Potential Therapeutic Strategy
Tomohiko Aoe
FRONTIERS IN PHARMACOLOGY (2020)
Reissuing the sigma receptors for SARS-CoV-2
Umit Haluk Yesilkaya et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2020)
Neurological associations of COVID-19
Mark A. Ellul et al.
LANCET NEUROLOGY (2020)
Crosstalk between endoplasmic reticulum stress and anti -viral activities: A novel therapeutic target for COVID-19
Aditi Banerjee et al.
LIFE SCIENCES (2020)
Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?
Antoni Sureda et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
Franck Touret et al.
SCIENTIFIC REPORTS (2020)
Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms
David E. Gordon et al.
SCIENCE (2020)
Mechanisms of SARS-CoV-2 Transmission and Pathogenesis
Andrew G. Harrison et al.
TRENDS IN IMMUNOLOGY (2020)
COVID-19 Infection-Preventing Clinical Deterioration
Christopher W. Seymour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 A Randomized Clinical Trial
Eric J. Lenze et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?
Jose Miguel Vela
FRONTIERS IN PHARMACOLOGY (2020)
Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic
Jonathan P. Rogers et al.
LANCET PSYCHIATRY (2020)
Endoplasmic Reticulum Stress Markers in SARS-COV-2 Infection and Pneumonia: Case-Control Study
Aylin Koseler et al.
IN VIVO (2020)
Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis
Dorian A. Rosen et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
Kenji Hashimoto
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2019)
The Molecular Function of σ Receptors: Past, Present, and Future
Hayden R. Schmidt et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Non-canonical Targets Mediating the Action of Drugs of Abuse: Cocaine at the Sigma-1 Receptor as an Example
Tsung-Ping Su
FRONTIERS IN NEUROSCIENCE (2019)
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Kai Zhang et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2019)
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Panos Zanos et al.
PHARMACOLOGICAL REVIEWS (2018)
Identification of the gene that codes for the σ2 receptor
Assaf Alon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Serum Interleukin-6 Is a Predictive Biomarker for Ketamine's Antidepressant Effect in Treatment-Resistant Patients With Major Depression
Jian-Jun Yang et al.
BIOLOGICAL PSYCHIATRY (2015)
Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication
Kenji Hashimoto
JOURNAL OF PHARMACOLOGICAL SCIENCES (2015)
Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells
Tamaki Ishima et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke
Roman Urfer et al.
STROKE (2014)
Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials
Taro Kishi et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2013)
Optimal Extent of Dopamine D2 Receptor Occupancy by Antipsychotics for Treatment of Dopamine Supersensitivity Psychosis and Late-Onset Psychosis
Masaomi Iyo et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2013)
Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression
Kenji Hashimoto
PROGRESS IN NEUROBIOLOGY (2013)
Old drug ifenprodil, new hope for PTSD with a history of childhood abuse
Kenji Hashimoto et al.
PSYCHOPHARMACOLOGY (2013)
Ifenprodil for the Treatment of Flashbacks in Adolescent Female Posttraumatic Stress Disorder Patients with a History of Abuse
Tsuyoshi Sasaki et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2013)
Ifenprodil for the Treatment of Flashbacks in Female Posttraumatic Stress Disorder Patients with a History of Childhood Sexual Abuse
Akira Kishimoto et al.
BIOLOGICAL PSYCHIATRY (2012)
Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases
Tomihisa Niitsu et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo
Matthew J. Robson et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia A Preliminary Study
Tomihisa Niitsu et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2012)
Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells by Ifenprodil: The Role of Sigma-1 and IP3 Receptors
Tamaki Ishima et al.
PLOS ONE (2012)
The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke
Karsten Ruscher et al.
BRAIN (2011)
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders
Teruo Hayashi et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered
Ian Hindmarch et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2010)
Fluvoxamine improved cognitive impairments in a patient with schizophrenia
Tomihisa Niitsu et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
Tsutomu Furuse et al.
ANNALS OF GENERAL PSYCHIATRY (2010)
Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors
Shinsui Kunitachi et al.
BRAIN RESEARCH (2009)
High occupancy of σ1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503
Masatomo Ishikawa et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2009)
Despite irreversible binding, PET tracer [11C]-SA5845 is suitable for imaging of drug competition at sigma receptors -: The cases of ketamine and haloperidol
Rudie Kortekaas et al.
NEUROCHEMISTRY INTERNATIONAL (2008)
Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth by Fluvoxamine: Role of Sigma-1 Receptors, IP3 Receptors and Cellular Signaling Pathways
Tomoko Nishimura et al.
PLOS ONE (2008)
Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: Role of sigma-1 receptors and IP3 receptors
Tamaki Ishima et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia
Masaomi Iyo et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma(1) receptor ligand
Teruo Hayashi et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Sigma-1 receptor chaperones at the ER-Mitochondrion interface regulate Ca2+ signaling and cell survival
Teruo Hayashi et al.
CELL (2007)
High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine:: A positron emission tomography study using [11C]SA4503
Masatomo Ishikawa et al.
BIOLOGICAL PSYCHIATRY (2007)
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: Role of sigma-1 receptors
Kenji Hashimoto et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Share Paper
